Nomura Holdings
ANIP icon

Nomura Holdings’s ANI Pharmaceuticals ANIP Stock Holding History

Nomura Holdings’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Sell
233,955
-3,270
-1% -$262K 0.02% 373
2026
Q1 		$18.2M Buy
237,225
+13,290
+6% +$1.04M 0.05% 267
2025
Q4 		$17.7M Buy
223,935
+28,417
+15% +$2.46M 0.02% 351
2025
Q3 		$17.9M Buy
195,518
+151,805
+347% +$12.4M 0.03% 343
2025
Q2 		$2.85M Sell
43,713
-173,463
-80% -$11.3M 0.01% 736
2025
Q1 		$14.5M Buy
217,176
+3,297
+2% +$197K 0.03% 370
2024
Q4 		$11.8M Buy
213,879
+3,255
+2% +$187K 0.02% 455
2024
Q3 		$12.6M Buy
+210,624
New +$12.8M 0.03% 381
2019
Q4 		– Sell
-405,511
Closed -$29.4M – 1093
2019
Q3 		$29.4M Buy
405,511
+30,062
+8% +$2.25M 0.11% 150
2019
Q2 		$31.1M Buy
375,449
+95,462
+34% +$6.79M 0.14% 130
2019
Q1 		$19.5M Buy
279,987
+209,441
+297% +$12.3M 0.08% 186
2018
Q4 		$3.17M Sell
70,546
-206,463
-75% -$10.8M 0.01% 604
2018
Q3 		$15.6M Sell
277,009
-33,106
-11% -$2.03M 0.05% 272
2018
Q2 		$20.7M Buy
310,115
+28,134
+10% +$1.76M 0.07% 230
2018
Q1 		$16.4M Sell
281,981
-2,280
-0.8% -$145K 0.03% 294
2017
Q4 		$18.3M Buy
284,261
+43,733
+18% +$2.72M 0.03% 306
2017
Q3 		$12.6M Buy
240,528
+31,179
+15% +$1.49M 0.03% 330
2017
Q2 		$9.74M Buy
209,349
+448
+0.2% +$21.6K 0.02% 379
2017
Q1 		$10.4M Buy
208,901
+1,164
+0.6% +$65.4K 0.03% 294
2016
Q4 		$12.6M Buy
207,737
+1,346
+0.7% +$82.3K 0.03% 319
2016
Q3 		$13.7M Buy
206,391
+25,327
+14% +$1.58M 0.04% 227
2016
Q2 		$10.1M Buy
181,064
+178,946
+8,449% +$8.7M 0.03% 285
2016
Q1 		$72K Sell
2,118
-164,632
-99% -$5.58M ﹤0.01% 1423
2015
Q4 		$7.52M Buy
166,750
+4,237
+3% +$182K 0.02% 303
2015
Q3 		$6.48M Buy
162,513
+11,016
+7% +$627K 0.02% 321
2015
Q2 		$9.01M Buy
151,497
+2,496
+2% +$149K 0.03% 284
2015
Q1 		$9.03M Buy
149,001
+138,589
+1,331% +$8.43M 0.03% 253
2014
Q4 		$567K Buy
+10,412
New +$459K ﹤0.01% 1582
2013
Q3 		– Sell
-9,928
Closed -$59K – 2317
2013
Q2 		$59K Buy
+9,928
New +$69.5K ﹤0.01% 2057

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's ANIP Position: Q2 2026 in Review

Nomura Holdings reduced its ANI Pharmaceuticals (ANIP) stake by 1.4% in Q2 2026, selling an estimated $262K and leaving 233,955 shares worth $19.4M. The position accounts for 0.02% of the portfolio, ranked #373.

Nomura Holdings first reported a position in ANIP in Q2 2013 and has held it in 29 quarters since. The position peaked at $31.1M in Q2 2019. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Nomura Holdings held 233,955 shares of ANI Pharmaceuticals worth $19.4M as of Q2 2026.
  • Nomura Holdings sold 3,270 ANI Pharmaceuticals shares in Q2 2026, an estimated $262K.
  • ANI Pharmaceuticals made up 0.02% of Nomura Holdings's portfolio in Q2 2026, its #373 holding.
  • Nomura Holdings first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 29 quarters since.
  • Nomura Holdings's ANI Pharmaceuticals position peaked at $31.1M in Q2 2019.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.